The Filing Desk

Foghorn Therapeutics vs Verastem

Foghorn Therapeutics FHTX · Verastem VSTM · Pharmaceuticals

Foghorn Therapeutics reported revenue of $31 million in fiscal 2025, about the same as Verastem's $31 million in fiscal 2025. Foghorn Therapeutics' revenue grew 36.8% in its latest year, and Verastem's grew 209.1%. Foghorn Therapeutics had an operating margin of -279.5%, against -550.3% at Verastem.

Side by side

Foghorn TherapeuticsVerastem
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$31M$31M
Revenue growth36.8%209.1%
Revenue growth a year, last 5 years138.6%−19.0%
Gross margin——
Operating margin−279.5%−550.3%
Net margin−240.3%−677.6%
Free cash flow−$86M—
Free cash flow margin−278.7%—
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count14.7%94.1%
Last close$1.78$6.86
P/E at the last close25.4×—
Insider trades, last 12 months—sold $680,195
Piotroski F-score2 of 8—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Foghorn TherapeuticsVerastem
Operating margin
Percent of revenue
Foghorn TherapeuticsVerastem
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Foghorn TherapeuticsVerastem

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Foghorn Therapeutics and Verastem pages.